BioCentury
ARTICLE | Company News

Indivior licenses preclinical addiction candidate from C4X Discovery

March 30, 2018 5:58 PM UTC

C4X Discovery Holdings plc (LSE:C4XD) licensed to Indivior plc (LSE:INDV) exclusive, worldwide rights to C4X3256, a preclinical compound to treat addiction. C4X will receive $10 million up front and is eligible for up to $284 million in development, regulatory and commercialization milestones, plus royalties.

C4X unveiled preclinical results on the selective orexin 1 receptor (OX1R; HCRTR1) antagonist at the meeting of the Society for Neuroscience in November, when it described how its NMR-based technology platform yielded an antagonist that could distinguish between OX1R and OX2R. C4X showed C4X3256 was efficacious in a rat model of nicotine addiction, and the company thinks the small molecule can treat a wide range of substance use disorders (see BioCentury Innovations, Jan. 4)...